Company Overview - Relay Therapeutics is a clinical-stage precision medicine company focused on transforming the drug discovery process through advanced computational and experimental technologies [2] - The company aims to develop life-changing therapies, particularly in targeted oncology and genetic disease indications [2] Financial Reporting - Relay Therapeutics will report its fourth quarter and full year 2024 financial results and corporate highlights on February 26, 2025, after U.S. financial markets close [1] Technology and Innovation - The company's Dynamo platform integrates various leading-edge computational and experimental approaches to target previously challenging protein targets in drug discovery [2] - Relay Therapeutics represents a new breed of biotech that combines complementary techniques and technologies to push the boundaries of drug discovery [2]

Core Insights - Relay Therapeutics, Inc. is a clinical-stage precision medicine company focused on transforming the drug discovery process through advanced computational and experimental technologies [3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 7:30 a.m. PT [1] - Relay Therapeutics aims to enhance small molecule therapeutic discovery in targeted oncology and genetic disease indications using its Dynamo® platform [3] Company Overview - Relay Therapeutics combines leading-edge computational and experimental approaches to address previously intractable protein targets in drug discovery [3] - The company is positioned at the intersection of complementary techniques and technologies, striving to push the boundaries of drug discovery [3] - More information about the company can be found on its website and social media platforms [3]

Core Insights - The Zacks rating system is centered around the changing earnings picture of a company, which is tracked through the Zacks Consensus Estimate for EPS from sell-side analysts for current and future years [1][2] Earnings Estimate Revisions - Relay Therapeutics has seen a 10.4% increase in the Zacks Consensus Estimate over the past three months, indicating a positive trend in earnings estimates [6] - The upgrade to a Zacks Rank 2 (Buy) reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices [9][10] Market Impact - Empirical research shows a strong correlation between earnings estimate revisions and near-term stock movements, suggesting that tracking these revisions can be beneficial for investment decisions [5][11] - Institutional investors often adjust their valuations based on earnings estimates, leading to significant price movements in stocks as they buy or sell based on these changes [11] Zacks Rating System - The Zacks rating system maintains a balanced approach with an equal proportion of 'buy' and 'sell' ratings across over 4000 stocks, with only the top 5% receiving a 'Strong Buy' rating [7] - The Zacks Rank stock-rating system has a proven track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [12] Future Earnings Outlook - Relay Therapeutics is expected to earn -$2.55 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 8.6% [13] - The upgrade positions Relay Therapeutics in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential for market-beating returns in the near term [15][16]

Core Viewpoint - Relay Therapeutics, Inc. (RLAY) has experienced significant selling pressure, resulting in a 27.9% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Technical Analysis - The Relative Strength Index (RSI) for RLAY is currently at 23.42, indicating that the stock may be oversold and could rebound as selling pressure exhausts [5] - The RSI is a momentum oscillator that helps identify potential price reversals, with a reading below 30 typically signaling an oversold condition [2][3] Earnings Estimates - There has been a strong consensus among sell-side analysts to raise earnings estimates for RLAY, leading to an 8.1% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [5] - RLAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, suggesting a potential turnaround [6]

Relay Therapeutics, Inc. (RLAY) has been beaten down lately with too much selling pressure. While the stock has lost 24% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscill ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company trans ...

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming ...

Relay Therapeutics, Inc. (RLAY) shares soared 6.7% in the last trading session to close at $8.11. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.8% gain over the past four weeks. The sudden surge in the stock price can be attributed to a positive investor mindset regarding the company's pipeline progress. Relay Therapeutics is leveraging its Dynamo platform to initially focus on precision oncology. The company has several can ...

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). The clinical benefit rate (CBR) was 57% in heavily pretreated patients. RLY-2608 is a pan-mutant and isoformselective inhibitor of PI3Kα. Oppenheimer downgraded Relay Therapeutics, noting the upcoming data from competitors. "We believe that approved PI ...

CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of c ...